Showing results (451-460 of 601) with videos related to
Sort By:
Pageof 61
Archives of Neurology|August 11, 2010
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?Clemens Warnke, Til Menge, Hans-Peter Hartung, et al.JAMA Neurology|February 16, 2026
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension StudyBruce A C Cree, Edward Fox, Hans-Peter Hartung, et al.Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension studyIvo N van Schaik, Orell Mielke, Vera Bril, et al.Journal of Neuroinflammation|May 28, 2013
The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitisPetra D Cravens, Bernd C Kieseier, Rehana Hussain, et al.Clinical Therapeutics|May 1, 2012
Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosisJohn P Caloyeras, Bin Zhang, Cheng Wang, et al.Neurology|August 12, 2016
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Gilles Edan, Mark S Freedman, et al.Neurology|April 1, 2014
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption studyRobert J Fox, Bruce A C Cree, Jerome De Sèze, et al.Journal of the Peripheral Nervous System : JPNS|April 14, 2017
International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndromeBart C Jacobs, Bianca van den Berg, Christine Verboon, et al.Therapeutic Advances in Neurological Disorders|October 14, 2024
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trialsTobias Derfuss, Robert Bermel, Chien-Ju Lin, et al.The Lancet. Neurology|June 15, 2013
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 studyKrzysztof Selmaj, David K B Li, Hans-Peter Hartung, et al.Pageof 61